A Mathematical Model for the Co-infection Dynamics of *Pneumocystis* Pneumonia and HIV/AIDS with Treatment

Michael Byamukama¹, Damian Kajunguri², Martin Karuhanga¹

¹Department of Mathematics, Mbarara University of Science and Technology,

P.O.Box 1410, Mbarara, Uganda.

²Department of Mathematics, Kabale University, P.O. Box 317, Kabale, Uganda.

Emails: mbyamukama@must.ac.ug, dkajunguri@kab.ac.ug, mkaruhanga@must.ac.ug ORCID1: 0000-0002-1357-4797, ORCID2: 0000-0001-7205-2561, ORCID3: 0000-0002-7254-9073

Abstract

The control of opportunistic infections among HIV infected individuals should be one of the major public health concerns in reducing mortality rate of individuals living with HIV/AIDS. In this study a deterministic co-infection mathematical model is developed to provide a quantification of treatment at each contagious stage against *Pneumocystis* Pneumonia (PCP) among HIV infected individuals on ART. The goal is to minimize the co-infection burden by putting the curable PCP under control. The disease-free equilibria for the HIV/AIDS sub-model, PCP sub-model and the co-infection model are shown to be locally asymptotically stable when their associated disease threshold parameter is less than a unity. By use of suitable Lyapunov functions, the endemic equilibria corresponding to HIV/AIDS and PCP sub-models are globally asymptotically stable whenever the HIV/AIDS related basic reproduction number \mathcal{R}_{0H} and the PCP related reproduction number \mathcal{R}_{0P} are respectively greater than a unity. The sensitivity analysis results implicate that the effective contact rates are the main mechanisms fueling the proliferation of the two diseases and on the other hand treatment efforts play an important role in reducing the incidence. The model numerical results reveal that PCP carriers have a considerable contribution in the transmission dynamics of PCP. Furthermore, treatment of PCP at all contagious phases significantly reduces the burden with HIV/AIDS and PCP co-infection.

Key words: HIV/AIDS, PCP Carriers, Basic reproduction number(s), Co-infection, Stability, Sensitivity analysis.

AMS subject classification 2010:34D23, 92D30, 93A030

1 Introduction

In absence of a curative formula, the Human Immunodeficiency Virus (HIV) that leads to Acquired Immunodeficiency Syndrome (AIDS) has traumatized the Sub-Saharan Africa since its discovery in 1981. HIV/AIDS persists to be a prime global public health concern, having claimed more than tens of millions lives so far

¹*Corresponding author: mbyamukama@must.ac.ug

and 650,000 people in 2021 alone [34]. There were 38.4 million people living with HIV/AIDS in 2021 of which the Sub-Saharan Africa accounts for almost 70% of the global HIV/AIDS infections [34].

The discovery of HIV as a pathogen that leads to AIDS and subsequent general utilization of anti-retroviral therapy (ART) have altered HIV from a definite cause of death to a manageable infection and this has significantly improved the longevity of HIV infected individuals [12, 37]. While HIV does not kill, if left untreated it minimizes the CD4 cell count in the body, which renders immune system incapable of fighting off infections and hence infected individuals advance to the fatal AIDS stage. This gives rise to many opportunistic infections such as *Pneumocystis* pneumonia (PCP), candidiasis, tuberculosis, cytomegalovirus, Hepatitis, and cancers like lymphoma, kaposis sarcoma, the list is infinite. Thus, early medication of HIV infectives with antiretroviral therapy (ART) can lower the viral load set point and thus prolonging the life of the infectives [14, 37].

In the last two decades, considerable global efforts have been mounted to address the HIV/AIDS epidemic, and significant progress has been made. The number of people newly infected with HIV, especially children, and the number of AIDS-related deaths have declined over the years, and the number of people with HIV receiving treatment increased to 28.7 million in 2021 [34].

Pneumocystis pneumonia (PCP) is a potentially life-threatening pulmonary infection caused by the fungus *Pneumocystis jirovecii* and has long been recognized in immunocompromised individuals and HIV-infected patients with a low CD4 cell count [15, 21, 28]. *Pneumocystis jiroveci* develops via airborne transmission or reactivation of improperly treated infection [13]. The clinical signs and symptoms include fever, shortness of breath with *hypoxemia*, and non-productive or dry cough. Specific diagnosis of PCP is possible using respiratory specimens with direct immunofluorescent staining and invasive procedures are required in order to prevent unnecessary treatments [13, 30]. There is no vaccine to fend off PCP but once infected, trimethoprim and sulfamethoxazole is the first-line agent for treatment [15]. To individuals living with HIV, trimethoprim sulfamethoxazole can be administered daily to reduce the risk of contracting PCP [21, 34].

Co-infections with HIV/AIDS and other linked diseases have evoked attention since the concurrent infection of one host with more than one different pathogens present shattering effects to the affected individual. The effect of ART and other preventive means on HIV/AIDS patients have been studied widely in [2, 22, 23, 25] and the results are promising so long as individuals do not default the treatment.

Not many researchers have studied the co-infection mathematical models for the dynamics of HIV/AIDS and pneumonia [24, 31, 32], other available works are clinical studies [3, 4, 17, 29] and systematic reviews [7, 19, 36]. In the study by Ntiiri *et al.* [24], the maximum protection against pneumonia and maximum protection against HIV/ AIDS would lower the rate of disease prevalence. Teklu and Mekonnen [31] developed a deterministic mathematical model considering treatment at each infection stage of the co-infection model from which they showed that increase in treatment at each infection stage, reduced the co-infected in-

dividuals at each of the respective stages. Teklu and Rao [32] modified [31] to incorporate vaccination. The combined effort of treatment against HIV/AIDS-pneumonia co-infection and vaccination strategy against pneumonia showed a reduction in the co-epidemic burden.

The studies in [24, 31] and [32] do not specify the strain of pneumonia under consideration since different strains have different causative agents and hence different treatment regiments. The studies further do not incorporate the role played by PCP carriers in the transmission dynamics of HIV/AIDS and PCP co-infection. The interference in the transmission chain of PCP among HIV/AIDS populace remains the only viable form to reduce the burden of the co-infection. Therefore, this study is designed with the aim of developing a *Pneumocystis* pneumonia-HIV/AIDS co-infection deterministic model that will investigate the role played by PCP carriers in the transmission of PCP among people living with HIV and further analyze the role of treatment of *Pneumocystis* pneumonia at all contagious phases in the co-infection dynamics of *Pneumocystis* pneumonia and HIV/AIDS. The developed model will guide on how properly the co-infection burden can be mitigated through treatment of carriers, infected and co-infected individuals and thus establishing a decisive directional strategy to policy makers.

This paper is organized as follows. In Section 2, we formulate a PCP and HIV/AIDS co-infection model with varying force of infection. A qualitative analysis of the model and its constituent sub-models is evaluated in Section 3, numerical results are provided in Section 4 and Section 5 discusses and concludes the study.

2 Model Formulation

2.1 Variables of the Model

The model subdivides the human population into ten mutually-exclusive compartments, namely susceptible individuals at risk of contracting HIV or *Pneumocystis* pneumonia (S(t)), carrier individuals who carry the PCP infection and can transmit the infection (C(t)), PCP-infected individuals who have active disease and are infectious $(I_P(t))$, PCP-recovered individuals who have been treated of the disease(R(t)), HIV infected individuals with no clinical symptoms of AIDS $(I_H(t))$, HIV-infected individuals with AIDS clinical symptoms $(I_A(t))$, individuals on treatment of HIV/AIDS $(I_T(t))$, HIV-infected individuals co-infected with PCP disease $(I_{HP}(t))$, HIV-infected individuals with AIDS symptoms co-infected with active PCP $(I_{AP}(t))$ and individuals on treatment of HIV/AIDS and PCP co-infection (T(t)). The total population at time t, denoted by N(t), is given by

$$N(t) = S(t) + C(t) + I_P(t) + R(t) + I_H(t) + I_A(t) + I_T(t) + I_{HP}(t) + I_{AP}(t) + T(t).$$

In the formulation of the model, it is assumed that HIV and PCP infected classes are susceptible to each other, there is no permanent immunity for PCP treated individuals and all PCP carriers progress to active PCP class if left untreated. It is further assumed that individuals in classes $I_T(t)$ and T(t) do not participate in transmission of HIV, since antiretroviral therapy reduces the viral load and subsequently lowering the probability of transmission.

2.2 Parameters of the Model and their Description

Table 1 below shows the parameters of the model and their description.

	Table 1: Parameters used in the model formulation and their description
Parameter	Definition
Λ	Per capita recruitment rate into susceptible population
μ	Per capita natural mortality rate of individuals
ν_P	Per capita PCP induced mortality rate
$ u_A$	Per capita AIDS induced mortality rate
ν	Per capita AIDS-PCP co-infection induced death rate
λ_1	Rate of progression from I_H class to I_A class in absence of treatment
λ_2	Rate of progression from I_{HP} class to I_{AP} class in absence of treatment
$ au_1$	Rate of treatment of HIV infected individuals
$ au_2$	Rate of treatment of AIDS patients
$ au_3$	Rate of treatment of HIV and PCP co-infected individuals
$ au_4$	Rate of treatment of AIDS and PCP co-infected individuals
β	Rate at which PCP carriers develop symptoms
ξ	Proportion of susceptible individuals that joins the PCP carriers
π	Per capita recovery rate of PCP carriers
γ	Rate at which treated PCP individuals become susceptible
ϵ	Per capita recovery rate of PCP infected individuals
ρ	Probability that a contact is efficient enough to cause a PCP infection
с	Average rate of contact with pneumonia infected individuals
ω	Transmission coefficient for the PCP carrier individuals
η	Probability that one will acquire HIV upon contact with an infected individual
k	Average contact rate with HIV infected individuals

2.3 Compartmental Diagram



Figure 1: A compartmental diagram for HIV/AIDS and PCP co-infection model.

2.4 Equations of the Model

Applying the assumptions, Figure 1, definitions of variables and parameters in Table 1, the HIV/AIDS and PCP deterministic co-infection model is obtained below.

$$\frac{dS}{dt} = \Lambda + \gamma R - (\alpha_P + \alpha_H + \mu)S,$$

$$\frac{dC}{dt} = \xi \alpha_P(t)S - (\alpha_H + \beta + \pi + \mu)C,$$

$$\frac{dI_P}{dt} = (1 - \xi)\alpha_P S + \beta C - (\alpha_H + \epsilon + \mu + \nu_P)I_P,$$

$$\frac{dR}{dt} = \epsilon I_P + \pi C - (\alpha_H + \gamma + \mu)R,$$

$$\frac{dI_H}{dt} = \alpha_H S + \alpha_H R - (\alpha_P + \tau_1 + \lambda_1 + \mu)I_H,$$

$$\frac{dI_A}{dt} = \lambda_1 I_H - (\alpha_P + \tau_2 + \mu + \nu_A)I_A,$$

$$\frac{dI_T}{dt} = \tau_1 I_H + \tau_2 I_A - \mu I_T,$$

$$\frac{dI_{HP}}{dt} = \alpha_H (C + I_P) + \alpha_P I_H - (\lambda_2 + \tau_3 + \mu + \nu_P)I_{HP},$$

$$\frac{dI_{AP}}{dt} = \alpha_P I_A + \lambda_2 I_{HP} - (\tau_4 + \mu + \nu)I_{AP},$$

$$\frac{dT}{dt} = \tau_3 I_{HP} + \tau_4 I_{AP} - \mu T,$$
(1)

where $t \ge 0$ with initial conditions $S(0) = S_0 > 0$, $C(0) = C_0 \ge 0$, $I_P(0) = I_{P0} \ge 0$, $I_P(0) = I_{P0} \ge 0$, $R(0) = R_0 \ge 0$, $I_H(0) = I_{H0} \ge 0$, $I_A(0) = I_{A0} \ge 0$, $I_T(0) = I_{T0} \ge 0$, $I_{HP}(0) = I_{HP0} \ge 0$, $I_{AP}(t) = I_{A0} \ge 0$, $I_{AP}(t) = I_{A0} \ge 0$, $I_{AP}(t) \ge 0$, $I_{AP}($

 $I_{AP0} \ge 0, \ T(0) = T_0 \ge 0.$

The rate at which *Pneumocystis* pneumonia spreads is defined as

$$\alpha_P(t) = \frac{\rho c(\omega C + I_P + \theta_1 I_{HP} + \theta_2 I_{AP})}{N(t)},$$

where $\theta_2 > \theta_1$ are modification parameters accounting for the assumed increased infectivity due to dual infection.

The rate at which HIV spreads is defined as

$$\alpha_H(t) = \frac{\eta k (I_H + a_1 I_{HP} + a_2 I_A + a_3 I_{AP})}{N(t)},$$

where $a_3 > a_2 > a_1$, are modification parameters showing the infectious rate per class with the assumption that I_{AP} individuals are more infectious of HIV than in individuals in classes I_A an I_{HP} due to high viral load [1, 23].

3 Analysis of the Model

3.1 Basic Properties of the Model

In this subsection, the basic properties of the solutions of model (1) which are essential in the proofs of stability are studied.

Lemma 3.1. The solutions $S(t), C(t), I_P(t), R(t), I_H(t), I_A(t), I_T(t), I_{HP}(t), I_{AP}(t)$ and T(t) of system (1) are non-negative for $t \ge 0$.

Proof. Let the initial values be non-negative, that is, $S(0) > 0, C(0) > 0, I_P(0) > 0, R(0) > 0, I_H(0) > 0, I_A(0) > 0,$

By contradiction, assume that there exists a first time t_1 such that

 $S(t_1) = 0, S'(t_1) < 0$ and $S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0$ for $0 < t < t_1$ or there exists a

$$\begin{split} t_2: C(t_2) &= 0, C'(t_2) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \ \text{for } 0 < t < t_1 \ \text{or there exists a} \end{split}$$

$$\begin{split} t_3: I_P(t_3) &= 0, I'_P(t_3) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \ \text{for } 0 < t < t_3 \ \text{or there exists a} \end{split}$$

$$\begin{split} t_4: R(t_4) &= 0, R'(t_4) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \ \text{for } 0 < t < t_4 \ \text{or there exists a} \end{split}$$

 $t_5: I_H(t_5) = 0, I'_H(t_5) < 0 \ S(t) > 0, \\ C(t) > 0, \\ I_P(t) > 0, \\ R(t) > 0, \\ I_H(t) > 0, \\ I_A(t) > 0, \\ I_T(t) > 0, \\ I_{HP}(t) > 0$

 $\begin{array}{l} 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_5 \mbox{ or there exists a} \\ t_6: I_A(t_6) = 0, I_A'(t_6) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_6 \mbox{ or there exists a} \\ t_7: I_T(t_7) = 0, I_T'(t_7) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_7 \mbox{ or there exists a} \\ t_8: I_{HP}(t_8) = 0, I_{HP}'(t_8) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_8 \mbox{ or there exists a} \\ t_9: I_{AP}(t_9) = 0, I_{AP}'(t_9) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_H(t) > 0, I_A(t) > 0, I_T(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_9 \mbox{ or there exists a} \\ t_{10}: T(t_{10}) = 0, C'(t_{10}) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_9 \mbox{ or there exists a} \\ t_{10}: T(t_{10}) = 0, C'(t_{10}) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_9 \mbox{ or there exists a} \\ t_{10}: T(t_{10}) = 0, C'(t_{10}) < 0 \ S(t) > 0, C(t) > 0, I_P(t) > 0, R(t) > 0, I_A(t) > 0, I_T(t) > 0, I_{HP}(t) > 0, I_{AP}(t) > 0, T(t) > 0 \mbox{ for } 0 < t < t_{10}. \ From system (1), we see that \\ \end{array}$

$$\begin{split} \frac{dS(t_1)}{dt} &= \Lambda + \gamma R(t_1) > 0, \\ \frac{dC(t_2)}{dt} &= \xi \alpha_P(t_2) S(t_2) > 0, \\ \frac{dI_P(t_3)}{dt} &= (1 - \xi) \alpha_P S(t_3) + \beta C(t_3) > 0, \\ \frac{dR(t_4)}{dt} &= \epsilon I_P(t_4) + \pi C(t_4) > 0, \\ \frac{dI_H(t_5)}{dt} &= \alpha_H S(t_5) + \alpha_H R(t_5) > 0, \\ \frac{dI_A(t_6)}{dt} &= \lambda_1 I_H(t_6) > 0, \\ \frac{dI_T(t_7)}{dt} &= \tau_1 I_H(t_7) + \tau_2 I_A(t_7) > 0, \\ \frac{dI_{HP}(t_8)}{dt} &= \alpha_H(t_8) \left(C(t_8) + I_P(t_8) \right) + \alpha_P I_H(t_8) > 0, \\ \frac{dI_{AP}(t_9)}{dt} &= \alpha_P(t_9) I_A(t_9) + \lambda_2 I_{HP}(t_9) > 0, \\ \frac{dT(t_{10})}{dt} &= \tau_3 I_{HP}(t_{10}) + \tau_4 I_{AP}(t_{10}) > 0, \end{split}$$

which leads to a contradiction and consequently, S(t), C(t), $I_P(t)$, R(t), $I_H(t)$, $I_A(t)$, $I_T(t)$, $I_{HP}(t)$, $I_{AP}(t)$ and T(t) remain positive. Therefore, the solutions of system (1) are non-negative for $t \ge 0$.

Lemma 3.2. The *Pneumocystis* pneumonia and HIV/AIDS co-infection model (1) is mathematically and epidemiologically well-posed.

Proof. By Lemma 3.1, $N(0) = N_0 > 0$. Adding the equations of system (1) gives

$$\frac{dN(t)}{dt} = \Lambda - \mu N(t) - \nu_P \left(I_P(t) + I_{HP}(t) \right) - \nu_A I_A(t) - \nu I_{AP}(t).$$
(2)

Since $I_P(t) \ge 0$, $I_A(t) \ge 0$, $I_{HP}(t) \ge 0$ and $I_{AP}(t) \ge 0$ for all $t \ge 0$, thus (2) gives the inequality

$$\frac{dN(t)}{dt} + \mu N(t) \le \Lambda.$$
(3)

With initial condition $N(0) = N_0$, integrate (3) to get

$$N(t) \le \frac{\Lambda}{\mu} + \left(N_0 - \frac{\Lambda}{\mu}\right)e^{-\mu t}.$$
(4)

As $t \to \infty$, we have $0 \le N(t) \le \frac{\Lambda}{\mu}$. Therefore, every feasible solution of model (1) that starts in region $\Omega = \left\{ \left(S(t), C(t), I_P(t), R(t), I_H(t), I_A(t), I_T(t), I_{HP}(t), I_{AP}(t), T(t) \right) \in \mathbb{R}^{10}_+ : N(t) \le \Lambda/\mu \right\}$ remains in this region for all values of $t \ge 0$ which implies that Ω is positively invariant and attracting. Hence the HIV/AIDS-PCP co-infection model (1) is mathematically and epidemiologically well-posed.

It is crucial to analyze the HIV/AIDS and PCP sub-models first and there after analyze the full coinfection model (1). This is done in order to have an insight on the transmission dynamics of the respective sub-models that are initial stages of a potential interaction between the two diseases.

3.2 Analysis of HIV/AIDS Sub-model

By setting $C(t) = I_P(t) = R(t) = I_{HP}(t) = I_{AP}(t) = T(t) = 0$, the following HIV/AIDS sub-model is obtained:

$$\frac{dS}{dt} = \Lambda - (\alpha_H + \mu)S,$$

$$\frac{dI_H}{dt} = \alpha_H S - (\tau_1 + \lambda_1 + \mu)I_H,$$

$$\frac{dI_A}{dt} = \lambda_1 I_H - (\tau_2 + \nu_A + \mu)I_A,$$

$$\frac{dI_T}{dt} = \tau_1 I_H + \tau_2 I_A - \mu I_T,$$
(5)

with

$$\alpha_H = \eta k \frac{(I_H + a_2 I_A)}{N_H},\tag{6}$$

so that

$$\frac{dN_H}{dt} = \Lambda - \mu N - \nu_A I_A,$$

3.2.1 Disease-Free Equilibrium of the HIV/AIDS Sub-model

The equilibria of system (5) are obtained by setting the right hand side of system (5) equal to zero. The disease-free equilibrium of the model describes the model in absence of the disease or infection. Thus with $I_H = I_A = 0$ and $I_T = 0$, we have $S = \Lambda/\mu$. Therefore, the HIV/AIDS-free equilibrium of (5) is given as $E_{0H} = (\Lambda/\mu, 0, 0, 0)$.

3.2.2 Computation of the Basic Reproduction Number of the HIV/AIDS Sub-model

Rephrasing the definition by Diekmann et al. [9], we define the HIV/AIDS basic reproduction number as the average number of secondary HIV infections caused by a single HIV infectious individual during his or her entire period of infectiousness. We use the next-generation matrix method as applied in [10, 26, 27, 35] to determine the basic reproduction number \mathcal{R}_{0H} of (5). Let \mathcal{F} denote the matrix of the new infection terms and \mathcal{V} be the matrix of the remaining transfer terms in system (5). Then we have

$$\mathcal{F} = \begin{bmatrix} \alpha_H S \\ 0 \end{bmatrix}, \mathcal{V} = \begin{bmatrix} (\tau_1 + \lambda_1 + \mu)I_H \\ -\lambda_1 I_H(t) + (\tau_2 + \nu_A + \mu)I_A(t) \end{bmatrix}.$$

We obtain the matrices F and V by finding the Jacobian matrices of \mathcal{F} and \mathcal{V} evaluated at the disease-free equilibrium respectively to obtain

$$F = \begin{bmatrix} \eta k & \eta k a_2 \\ 0 & 0 \end{bmatrix}, V = \begin{bmatrix} q_1 & 0 \\ -\lambda & q_2 \end{bmatrix},$$

where $q_1 = \tau_1 + \lambda_1 + \mu$ and $q_2 = \tau_2 + \nu_A + \mu$.

Thus, the basic reproduction number is given by

$$\mathcal{R}_{0H} = \mathcal{K}(FV^{-1}) = \frac{\eta k}{q_1 q_2} \big(q_2 + a_2 \lambda_1 \big),$$

where \mathcal{K} represents the spectral radius of FV^{-1} .

3.2.3 Endemic Equilibrium Point of the HIV/AIDS Sub-model

The endemic equilibrium point denoted by E_{eH} is defined as a steady state solution for system (5) which occurs when there is persistence of the HIV/AIDS in a community. Equating the right hand side equal to zero of system (5) and solving for S, I_H, I_A and I_T yields $E_{eH} = (S_e, I_{He}, I_{Ae}, I_{Te})$, where

$$S_{e} = \frac{N_{H}q_{1}q_{2}}{\eta k(q_{2} + a_{2}\lambda_{1})},$$

$$I_{He} = \frac{\mu N_{H}q_{1}q_{2} - \Lambda \eta k(q_{2} + a_{2}\lambda_{1})}{q_{1}\eta k(q_{2} + a_{2}\lambda_{1})},$$

$$I_{Ae} = \frac{\lambda_{1}(\mu N_{H}q_{1}q_{2} - \Lambda \eta k(q_{2} + a_{2}\lambda_{1}))}{q_{1}q_{2}\eta k(q_{2} + a_{2}\lambda_{1})},$$

$$I_{Te} = \frac{\mu N_{H}q_{1}q_{2} - \Lambda \eta k(q_{2} + a_{2}\lambda_{1})}{\mu q_{1}\eta k(q_{2} + a_{2}\lambda_{1})} \left(\tau_{1} + \frac{\tau_{2}\lambda_{1}}{q_{2}}\right)$$

where $N_H = \frac{\Lambda \eta k (q_1 q_2 + \nu_A \lambda_1) (q_2 + a_2 \lambda_1)}{q_1 q_2 \left(\mu \eta k (q_2 + a_2 \lambda_1) + \nu_A \lambda_1 \right)}.$

Lemma 3.3. The HIV/AIDS sub-model (5) has a unique endemic equilibrium point if $\mathcal{R}_{0H} > 1$.

Proof. If the disease is endemic in the community, then $\frac{dI_H}{dt} > 0$ and $\frac{dI_A}{dt} > 0$ that is

$$\eta k (I_H + a_2 I_A) \frac{S}{N} - q_1 I_H > 0, \tag{7}$$

$$\lambda_1 I_H - q_2 I_A > 0. \tag{8}$$

From (7) and using the fact that $\frac{S}{N} < 1$, we have

$$I_H < \frac{\eta k a_2 I_A}{q_1 - \eta k}.\tag{9}$$

From (8), we have

$$I_A < \frac{\lambda_1 I_H}{q_2}.\tag{10}$$

Inequalities (9) and (10) together imply

$$1 < \frac{\eta k}{q_1 q_2} (q_2 + a_2 \lambda_1) = \mathcal{R}_{0H}$$

Thus, a unique endemic equilibrium point E_{eH} exists when $\mathcal{R}_{0H} > 1$.

3.2.4 Local and Global Stability of HIV/AIDS Sub-Model Disease-Free Equilibrium

Lemma 3.4. The HIV/AIDS-free equilibrium E_{0H} is locally asymptotically stable if $\mathcal{R}_{0H} < 1$ and unstable otherwise.

Proof. For E_{0H} to be locally asymptotically stable, the Jacobian matrix $J_{E_{0H}}$ of sub-model (5) should have negative eigenvalues or equivalently a negative trace and a positive determinant.

$$J_{E_{0H}} = \begin{bmatrix} -\mu & -\eta k & -\eta k a_2 & 0\\ 0 & \eta k - q_1 & \eta k a_2 & 0\\ 0 & \lambda_1 & -q_2 & 0\\ 0 & \tau_1 & \tau_2 & -\mu \end{bmatrix}.$$
 (11)

The first and fourth columns of the Jacobian matrix (11) clearly show that $-\mu$ is a repeated negative eigenvalue. The other two eigenvalues can be obtained by reducing the Jacobian matrix (11) into a 2 × 2 matrix given by

$$J_{E_{0H}}^{*} = \begin{bmatrix} \eta k - q_1 & \eta k a_2 \\ \lambda_1 & -q_2 \end{bmatrix}.$$
(12)

We now employ the trace determinant strategy on (12) such that

$$tr(J_{E_{0H}}) = \eta k - (q_1 + q_2) < 0 \text{ if } \eta k < q_1 + q_2.$$
(13)

From $\mathcal{R}_{0H} = \frac{\eta k}{q_1 q_2} (q_2 + a_2 \lambda_1)$, it is easy to see that (13) gives

$$\frac{\eta k}{q_1 q_2} (q_2 + a_2 \lambda_1) < \frac{q_1 + q_2}{q_1 q_2} (q_2 + a_2 \lambda_1),$$

$$\mathcal{R}_{0H} < \frac{q_1 + q_2}{q_1 q_2} (q_2 + a_2 \lambda_1).$$
(14)

Thus $tr(J_{E_{0H}}) < 0$ if $\mathcal{R}_{0H} < \frac{q_1+q_2}{q_1q_2} (q_2 + a_2\lambda_1)$. We now consider $\det(J_{E_{0H}}) = -\eta k(q_2 + \lambda_1 a_2) + q_1q_2 > 0$ if $\eta k(q_2 + \lambda_1 a_2) < q_1q_2$. Therefore,

$$\mathcal{R}_{0H} = \frac{\eta k}{q_1 q_2} \left(q_2 + a_2 \lambda_1 \right) < 1 \implies \det(J_{E_{0H}}) > 1 \text{ if } \mathcal{R}_{0H} < 1.$$

$$\tag{15}$$

Thus, E_{0H} is locally asymptotically stable if and only if the inequalities (14) and (15) hold.

Theorem 1. The disease-free equilibrium E_{0H} of system (5) is globally asymptotically stable if $\mathcal{R}_{0H} < 1$ and unstable otherwise. The disease free equilibrium E_{0H} is the only equilibrium when $\mathcal{R}_{0H} \leq 1$.

Proof. Let

$$W = \psi_1 I_H + \psi_2 I_A,\tag{16}$$

be the Lyapunov function which involves individuals who contribute to HIV/AIDS in the population where ψ_1 and ψ_2 are non-negative constants. The time derivative of the Lyapunov function (16) is given by

$$\frac{dW}{dt} = \psi_1 (\alpha_H S - q_1 I_H) + \psi_2 (\lambda_1 - q_2 I_A),
\leq ((\eta k - q_1)\psi_1 + \psi_2 \lambda_1) I_H + (\psi_1 \eta k a_2 - \psi_2 q_2) I_A.$$
(17)

Fixing $\psi_1 > 0$ and setting $\psi_2 = \frac{1}{q_2} \eta k a_2 \psi_1$, we obtain

$$\begin{aligned} \frac{dW}{dt} &\leq q_1 \psi_1 \Big(\frac{\eta k (q_2 + \lambda_1 a_2)}{q_1 q_2} - 1 \Big) I_H + \frac{q_1 q_2 \psi_1}{\lambda_1} \Big(\frac{\eta k (q_2 + a_2 \lambda_1)}{q_1 q_2} - 1 \Big) I_A, \\ &= \Big(q_1 \psi_1 I_H + \frac{q_1 q_2 \psi_1}{\lambda_1} I_A \Big) \Big(\mathcal{R}_{0H} - 1 \Big). \end{aligned}$$

Thus, $\frac{dW}{dt} \leq 0$ when $\mathcal{R}_{0H} \leq 1$. Furthermore, $\frac{dW}{dt} = 0$ if and only if either $I_H = I_A = 0$ or $\mathcal{R}_{0H} = 1$. In either case, the largest compact invariant subset of $\Omega_1 = \{S(t), I_H(t), I_A(t), I_T(t) \in \mathbb{R}^4_+ : \frac{dW}{dt} = 0\}$ is the singleton E_{0H} . By Lasalle's Invariance Principle [11, 18], E_{0H} is globally stable in \mathbb{R}^4_+ provided $\mathcal{R}_{0H} \leq 1$.

3.2.5 Local and Global Stability of the HIV/AIDS Endemic Equilibrium

Theorem 2. The endemic equilibrium point E_{eH} is locally asymptotically stable if $\mathcal{R}_{0H} > 1$, otherwise it is unstable.

Proof. To show the local stability of the endemic equilibrium point, the method of Routh-Hurwitz stability criteria is employed [8, 27]. The Jacobian matrix of the system (5) evaluated at the endemic equilibrium

point E_{eH} is

$$J_{E_{eH}} = \begin{bmatrix} -B_1 & -B_3 & -B_4 & 0\\ \alpha_H^* & B_2 & B_5 & 0\\ 0 & \lambda_1 & -q_2 & 0\\ 0 & \tau_1 & \tau_2 & -\mu \end{bmatrix},$$
(18)

where $B_1 = (\alpha_H^* + \mu), B_2 = \eta k / \mathcal{R}_{0H} - q_1, B_3 = \eta k / \mathcal{R}_{0H}, B_4 = B_5 = \eta k a_2 / \mathcal{R}_{0H}, q_1 = (\tau_1 + \lambda_1 + \mu), q_2 = (\tau_2 + \nu_A + \mu)$ and α_H^* is the force of HIV infection evaluated at the disease endemic equilibrium point. The characteristic equation of Jacobian (18) is given by

$$P(\lambda) = \det \begin{bmatrix} \lambda + B_1 & B_3 & B_4 & 0 \\ -\alpha_H^* & \lambda - B_2 & -B_5 & 0 \\ 0 & -\lambda_1 & \lambda + q_2 & 0 \\ 0 & -\tau_1 & -\tau_2 & \lambda + \mu \end{bmatrix},$$

$$= (\lambda + \mu) \Big(\lambda^3 + (B_1 + q_2 - B_2) \lambda^2 + (B_1(q_2 - B_2) + B_3 \alpha_H^* - B_2 q_2 - \lambda_1 B_5) \lambda + (B_3 q_2 + B_4 \lambda_1) \alpha_H^* - (B_2 q_2 + \lambda_1 B_5) B_1 \Big).$$
(19)

From characteristic equation (19), we have $\lambda = -\mu < 0$ and

$$\lambda^3 + a_1 \lambda^2 + a_2 \lambda + a_3 = 0, \tag{20}$$

where

$$\begin{aligned} a_1 &= B_1 + q_1 - B_2 = \alpha_H^* + q_1 + q_2 + \mu - \eta k / \mathcal{R}_{0H} > 0 \text{ if } \mathcal{R}_{0H} > 1, \\ a_2 &= B_1(q_2 - B_2) + B_3 \alpha_H^* - B_2 q_2 - \lambda_1 B_5 = (\alpha_H^* + \mu)(q_1 + q_2 - \eta k / \mathcal{R}_{0H}) + q_1 q_2 / \mathcal{R}_{0H}(\mathcal{R}_{0H} - 1) > 0 \text{ if } \mathcal{R}_{0H} > 1, \\ a_3 &= \alpha_H^*(B_3 q_2 + B_4 \lambda_1) - B_1(B_2 q_2 + B_5 \lambda_1) = \eta k / \mathcal{R}_{0H}(\alpha_H^* q_2 + a_2 \lambda_1) + (\alpha_H^* + \mu) / \mathcal{R}_{0H}(\mathcal{R}_{0H} - 1) > 0 \text{ if } \mathcal{R}_{0H} > 1. \end{aligned}$$

It has been estalished that for $\mathcal{R}_{0H} > 1$, a_1, a_2, a_3 are positive and we now compute $a_1a_2 - a_3$ to get

$$a_1 a_2 - a_3 = \left(\alpha_H^* + q_1 + q_2 + \mu - \frac{\eta k}{\mathcal{R}_{0H}}\right) \left((\alpha_H^* + \mu)(q_1 + q_2 - \frac{\eta k}{\mathcal{R}_{0H}}\right) + \frac{q_1 q_2}{\mathcal{R}_{0H}}(\mathcal{R}_{0H} - 1) \left(q_1 + q_2 - \frac{\eta k}{\mathcal{R}_{0H}}\right) > 0, \text{ if } \mathcal{R}_{0H} > 1.$$

The Routh-Hurwitz conditions $(a_1 > 0, a_2 > 0, a_3 > 0, a_1a_2 > a_3)$ for characteristic equation (20) are satisfied whenever $\mathcal{R}_{0H} > 1$. Hence, the endemic equilibrium point of system (5) is locally asymptotically stable.

Theorem 3. If $\mathcal{R}_{0H} > 1$, the endemic equilibrium point E_{eH} of the model (5) is globally asymptotically stable.

Proof. To establish the global stability of the endemic equilibrium E_{eH} , the following Lyapunov function $\mathcal{W}(S, I_H, I_A, I_T)$ is constructed as

$$\mathcal{W} = \left(S - S_e + S_e \ln \frac{S_e}{S}\right) + \left(I_H - I_{He} + I_{He} \ln \frac{I_{He}}{I_H}\right) + \left(I_A - I_{Ae} + I_{Ae} \ln \frac{I_{Ae}}{I_A}\right) + \left(I_T - I_{Te} + I_{Te} \ln \frac{I_{Te}}{I_T}\right)$$
(21)

It is clear that $\mathcal{W}(S_e, I_{He}, I_{Ae}, I_{Te}) = 0$, and $\mathcal{W} > 0$ otherwise. Moreover, W is radially unbounded in \mathbb{R}^4_+ . We now seek to determine the sign of $d\mathcal{W}/dt$ by differentiating (21) with respect to t as follows

$$\frac{d\mathcal{W}}{dt} = \left(1 - \frac{S_e}{S}\right)\frac{dS}{dt} + \left(1 - \frac{I_{He}}{I_H}\right)\frac{dI_H}{dt} + \left(1 - \frac{I_{Ae}}{I_A}\right)\frac{dI_A}{dt} + \left(1 - \frac{I_{Te}}{I_T}\right)\frac{dI_T}{dt}.$$
(22)

Substituting for dS/dt, dI_H/dt , dI_A/dt and dI_T/dt into (22) gives

$$\frac{dW}{dt} = \left(1 - \frac{S_e}{S}\right) \left(\Lambda - (\alpha_H + \mu)\right) + \left(1 - \frac{I_{He}}{I_H}\right) \left(\alpha_H - q_1 I_H\right) + \left(1 - \frac{I_{Ae}}{I_A}\right) \left(\lambda_1 I_H - q_2 I_A\right) \\
+ \left(1 - \frac{I_{Te}}{I_T}\right) \left(\tau_1 I_H + \tau_2 I_A - \mu I_T\right), \\
= \Lambda + (\alpha_H + \mu) S_e + \alpha_H S + q_1 I_{He} + (\lambda_1 + \tau_1) I_H + q_2 I_{Ae} + \tau_2 I_A + \mu I_{Te} - \left(\Lambda \frac{S_e}{S} + \left(\alpha_H (1 + \frac{I_{He}}{I_H}) + \mu\right) S + \left(q_1 + \lambda_1 \frac{I_{Ae}}{I_A} + \tau_1 \frac{I_{Te}}{I_T}\right) I_H + \left(q_2 + \tau_2 \frac{I_{Te}}{I_T}\right) I_A + \mu I_T\right), \\
\frac{dW}{dt} = P - Q.$$
(23)

From (23), we have $P = \Lambda + (\alpha_H + \mu)S_e + \alpha_H S + q_1 I_{He} + (\lambda_1 + \tau_1)I_H + q_2 I_{Ae} + \tau_2 I_A + \mu I_{Te}$ and $Q = \Lambda \frac{S_e}{S} + (\alpha_H (1 + \frac{I_{He}}{I_H}) + \mu)S + (q_1 + \lambda_1 \frac{I_{Ae}}{I_A} + \tau_1 \frac{I_{Te}}{I_T})I_H + (q_2 + \tau_2 \frac{I_{Te}}{I_T})I_A + \mu I_T.$

Therefore from (23), if P < Q, then $\frac{dW}{dt}$ will be negative definite, implying that $\frac{dW}{dt} < 0$. It is also clear that $\frac{dW}{dt} = 0$ if and only if $S = S_e$, $I_H = I_{He}$, $I_A = I_{Ae}$ and $I_T = I_{Te}$.

Therefore, the largest compact invariant set in $\{(S, I_H, I_A, I_T) \in \Omega_1 : \frac{d\mathcal{W}}{dt} = 0\}$ is the singleton $\{E_{eH}\}$ where E_{eH} is the endemic equilibrium point of system (5). By La Salle's invariant principle [11, 16, 18], it implies that E_{eH} is globally asymptotically stable in Ω_1 if $P \leq Q$, which holds if and only if $\mathcal{R}_{0H} > 1$.

3.3 Analysis of *Pneumocystis* Pneumonia Sub-model

We obtain the PCP sub-model when $I_H(t) = I_A(t) = I_T(t) = I_{HP}(t) = I_{AP} = T(t) = 0$ in system 1, which gives

$$\frac{dS}{dt} = \Lambda + \gamma R - (\alpha_P + \mu)S,$$

$$\frac{dC}{dt} = \xi \alpha_P S - (\beta + \pi + \mu)C,$$

$$\frac{dI_P}{dt} = (1 - \xi)\alpha_P S + \beta C - (\epsilon + \nu_P + \mu)I_P,$$

$$\frac{dR}{dt} = \pi C + \epsilon I_P - (\gamma + \mu)R,$$

$$N_P = S + C + I_P + R.$$
(24)

3.3.1 Disease-Free Equilibrium of the PCP Sub-model

The disease free equilibrium point of model (24) describes the model in absence of PCP that is the carrier and infected classes are zero which gives, $C = I_P = 0, R = 0$ and $S = \Lambda/\mu$. Therefore, the disease-free equilibrium point denoted by $E_{0P} = (S, C, I_P, R)$ is $E_{0P} = (\Lambda/\mu, 0, 0, 0)$.

3.3.2 Pneumocystis Pneumonia Basic Reproduction Number

Following a similar procedure in sub-subsection 3.2.2, the PCP basic reproduction number is computed and obtained as

$$\mathcal{R}_{0P} = \frac{\rho c}{k_1 k_2} \Big(\xi (k_2 \omega + \beta) + (1 - \xi) k_1 \Big).$$

3.3.3 Endemic Equilibrium Point

The endemic equilibrium point denoted by E_{eP} is defined as a steady state solution for system (24) and it occurs when there is a persistence of *Pneumocystis* Pneumonia. Hence, $E_{eP} = (S_e, C_e, I_{Pe}, R_e)$ can be determined by solving system (24) with the right hand side equal to zero, from which we obtain,

$$S_{e} = \frac{k_{1}k_{2}N_{P}}{\rho c ((1-\xi)k_{1}+\xi(\omega k_{2}+\beta))},$$

$$C_{e} = \frac{\xi k_{2}k_{3} (\mu k_{1}k_{2}N_{P} - \Lambda \rho c ((1-\xi)k_{1}+\xi(\omega k_{2}+\beta))))}{A},$$

$$I_{Pe} = \frac{k_{3} ((1-\xi)k_{1}+\xi\beta) (\mu k_{1}k_{2}N_{P} - \Lambda \rho c ((1-\xi)k_{1}+\xi(\omega k_{2}+\beta)))}{A},$$

$$R_{e} = \frac{(\mu k_{1}k_{2}N_{P} - \Lambda \rho c ((1-\xi)k_{1}+\xi(\omega k_{2}+\beta)))}{A} (\pi \xi k_{2} + \epsilon ((1-\xi)k_{1}+\xi\beta)),$$

$$14$$

together with
$$A = \rho c \Big((1-\xi)k_1 + \xi\beta \Big) \Big(\xi k_2 \gamma \pi - k_1 k_2 k_3 + \gamma \epsilon \big((1-\xi)k_1 + \xi\beta \big) \Big)$$
 and

$$N_P = \frac{\Lambda \Big(A + \nu_P \rho c k_3 \big(1-\xi)k_1 + \xi\beta \big) \big((1-\xi)k_1 + \xi(\omega k_2 + \beta) \big) \Big)}{\mu A - \nu_P \mu k_1 k_2 k_3 \big((1-\xi)k_1 + \xi\beta \big)}.$$

Lemma 3.5. For $\mathcal{R}_{0P} > 1$, the system (24) has a unique endemic equilibrium point E_e and no endemic equilibrium otherwise.

Proof. If the disease persists in the community, then $\frac{dC}{dt} > 0$ and $\frac{dI_P}{dt} > 0$, that is,

$$\xi \alpha_P S - k_1 C = \xi \rho c (\omega C + I_P) \frac{S}{N} - k_1 C > 0, \qquad (25)$$

$$(1-\xi)\alpha_P S + \beta - k_2 I_P = (1-\xi)\rho c(\omega C + I_P)\frac{S}{N} + \beta C - k_2 I_P > 0.$$
⁽²⁶⁾

From inequality (25) and applying the fact that $S/N \leq 1$, we have

$$C < \frac{\xi \rho c I_P}{k_1 - \xi \rho c \omega},\tag{27}$$

Inequalities (26) and (27), together imply

$$\mathcal{R}_{0P} = \frac{\rho c}{k_1 k_2} \Big((1 - \xi) k_1 + \xi (\beta + k_2 \omega) \Big) > 1.$$

Thus, a unique endemic equilibrium point exists when $\mathcal{R}_{0P} > 1$.

3.3.4 Local and Global Stability of PCP Free Equilibrium

Theorem 4. The disease-free equilibrium point E_{0P} of system (24) is locally asymptotically stable whenever $\mathcal{R}_{0P} < 1$ and unstable whenever $\mathcal{R}_{0P} > 1$.

Proof. The Jacobian matrix of sub-model system (24) evaluated at the disease-free equilibrium point E_{0P} is given as

$$J_{(E_{0P})} = \begin{bmatrix} -\mu & -\rho c \omega & -\rho c & \gamma \\ 0 & \xi \rho c \omega - k_1 & \xi \rho c & 0 \\ 0 & (1-\xi)\rho c \omega + \beta & (1-\xi)\rho c - k_2 & 0 \\ 0 & \pi & \epsilon & -k_3 \end{bmatrix}.$$
 (28)

Thus, from the Jacobian matrix (28), we obtain the characteristic equation;

$$P(\lambda) = (\lambda + \mu)(\lambda + k_3) \Big(\lambda^2 + a_1 \lambda + a_0\Big),$$
(29)

where $a_1 = k_1 + k_2 - \rho c((1 - \xi) + \xi \omega) > 0$ and $a_0 = k_1 k_2 (1 - \mathcal{R}_{0P}) > 0$ if $\mathcal{R}_{0P} < 1$.

Clearly the roots of (29) $\lambda = -\mu$, $\lambda = -k_3$ are negative and by Routh-Hurwitz criterion, the characteristic polynomial $\lambda^2 + a_1\lambda + a_0$ has negative eigenvalues if $a_0 > 0, a_1 > 0$ which is satisfied when $\mathcal{R}_{0P} < 1$. Therefore, since all the eigenvalues of (28) are negative whenever $\mathcal{R}_{0P} < 1$, the disease-free equilibrium point of system (24) is locally asymptotically stable. We now deploy the method described by Castillo-Chavez *et al.* [5] to study the global asymptotic stability of the disease-free equilibrium. Re-write the model system (24) as

$$\frac{dX_1}{dt} = \mathcal{F}(X_1, X_2),$$

$$\frac{dX_2}{dt} = \mathcal{G}(X_1, X_2),$$

$$\mathcal{G}(X_1, 0) = 0,$$
(30)

where $X_1 = (S, R)$ represents the uninfected population and $X_2 = (C, I_P)$ represents the infected population. The disease-free equilibrium of the model is denoted by $E_{0P} = (X^*, 0)$, where $X^* = (\Lambda/\mu, 0, 0, 0)$.

Theorem 5. The disease free-equilibrium point E_{0P} is globally asymptotically stable if $\mathcal{R}_{0P} < 1$ and the following conditions should hold;

- (T1) for $\frac{dX_1}{dt} = \mathcal{F}(X_1, 0), X^*$ is globally asymptotically stable,
- (T2) $\mathcal{G}(X_1, X_2) = AX_2 \tilde{\mathcal{G}}(X_1, X_2), \quad \tilde{\mathcal{G}}(X_1, X_2) \ge 0 \text{ for } (X_1, X_2) \in \Omega_2 \text{ and } A = \frac{\partial \mathcal{G}(X_1^*, 0)}{\partial X_2} \text{ is an } M \text{matrix}$ (the off diagonal elements are non-negative) and Ω_2 is the invariant region.

Proof. From system (24), it follows that

$$\mathcal{F}(X_1, X_2) = \begin{bmatrix} \Lambda + \gamma R - (\alpha_P + \mu)S \\ \pi C + \epsilon I_P - (\gamma + \mu)R \end{bmatrix},$$

$$\mathcal{G}(X_1, X_2) = \begin{bmatrix} \xi \alpha_P S - k_1 C \\ (1 - \xi)\alpha_P S + \beta C - k_2 I_P \end{bmatrix}.$$
 (31)

Consider $\mathcal{F}(X_1, 0) = \begin{bmatrix} \Lambda - \mu S \\ 0 \end{bmatrix}$, and as $t \to \infty$, its observed that $X_1 \to E_{0P}$ that is, $S \to \Lambda/\mu$. Thus, there is convergence in Ω_2 implying that (T1) holds.

Now

$$A = \frac{\partial \mathcal{G}(X_1^*, 0)}{\partial X_2} = \begin{bmatrix} -k_1 + \xi \rho c \omega & \xi \rho c \\ \beta + (1 - \xi) \rho c \omega & -k_2 + (1 - \xi) \rho c \end{bmatrix},$$
(32)

and

$$\tilde{\mathcal{G}}(X_1, X_2) = AX_2 - \mathcal{G}(X_1, X_2) = \begin{bmatrix} \xi \rho c \left(1 - \frac{S}{N}\right) \left(\omega C + I_P\right) \\ \left(1 - \xi\right) \rho c \left(1 - \frac{S}{N}\right) \left(\omega C + I_P\right) \end{bmatrix}.$$
(33)

Clearly from (32), A is an M-matrix and from (33), $\tilde{\mathcal{G}}(X_1, X_2) \ge 0$ since $\frac{S}{N} \le 1$ implying that (T2) holds. Since both (T1) and (T2) hold, then E_{0P} is globally asymptotically stable.

3.3.5 Global stability of PCP Endemic Equilibrium

Theorem 6. : If $\mathcal{R}_{0P} > 1$, the endemic equilibrium E_{eP} of the system (24) is globally asymptotically stable.

Proof. Systematically, we define an appropriate Lyapunov function $L(S, C, I_P, R)$ such that

$$L = \left(S - S_e + S_e \ln \frac{S_e}{S}\right) + \left(C - C_e + C_e \ln \frac{C_e}{C}\right) + \left(I_P - I_{Pe} + I_{Pe} \ln \frac{I_{Pe}}{I_P}\right) + \left(R - R_e + R_e \ln \frac{R_e}{R}\right).$$
(34)

Note that $L(S_e, C_e, I_{Pe}, R_e) = 0$ and W > 0 otherwise. Differentiating equation (34) with respect to t, yields

$$\frac{dL}{dt} = \left(1 - \frac{S_e}{S}\right)\frac{dS}{dt} + \left(1 - \frac{C_e}{C}\right)\frac{C}{dt} + \left(1 - \frac{I_{Pe}}{I_P}\right)\frac{dI_{Pe}}{dt} + \left(1 - \frac{R_e}{R}\right)\frac{dR_e}{dt}.$$
(35)

Substituting expressions for $\frac{dS}{dt}$, $\frac{dC}{dt}$, $\frac{dI_P}{dt}$, and $\frac{dR}{dt}$ in equation (35), gives

$$\begin{aligned} \frac{dL}{dt} &= \left(1 - \frac{S_e}{S}\right) (\Lambda + \gamma R - (\alpha_P + \mu)S) + \left(1 - \frac{C_e}{C}\right) (\xi \alpha_P S - k_1 C) \\ &+ \left(1 - \frac{I_{Pe}}{I_P}\right) ((1 - \xi) \alpha_P S + \beta C - k_2 I_P) + \left(1 - \frac{R_e}{R}\right) (\pi C + \epsilon I_P - (\mu + \beta)R), \end{aligned}$$

$$&= \Lambda + \gamma R + (\alpha_P + \mu)S_e + \alpha_P S + k_1 C_e + (\beta + \pi)C + \epsilon I_P + (\mu + \beta)R_e - \left(S(\alpha_P + \mu + \xi \alpha_P \frac{C_e}{C} + (1 - \xi)\alpha_P \frac{I_{Pe}}{I_P}\right) + \frac{S_e}{S} (\lambda + \gamma R) + k_1 C + k_2 I_P + \beta C \frac{I_{Pe}}{I_P} + (\pi C + \epsilon I_P) \frac{R_e}{R} + (\mu + \beta)R), \end{aligned}$$

$$&= \Lambda - B, \end{aligned}$$
(36)

where

$$\begin{split} A &= \Lambda + \gamma R + (\alpha_p + \mu)S_e + \alpha_P S + k_1 C_e + (\beta + \pi)C + \epsilon I_P + (\mu + \beta)R_e, \\ B &= S\left(\alpha_P + \mu + \xi \alpha_P \frac{C_e}{C} + (1 - \xi)\alpha_P \frac{I_{Pe}}{I_p}\right) + \frac{S_e}{S}(\lambda + \gamma R) + k_1 C + k_2 I_P + \beta C \frac{I_{Pe}}{I_P} + (\pi C + \epsilon I_P) \frac{R_e}{R} + (\mu + \beta)R. \\ \text{Thus if } A < B, \text{ we obtain } \frac{dL}{dt} \leq 0 \text{ and } \frac{dL}{dt} = 0 \text{ if and only if } S = S_e, C = C_e, I_P = I_{Pe}, R = R_e. \text{ Therefore,} \\ \text{the largest compact invariant set in } \{(S, C, I_P, R) \in \Omega_2 : \frac{dL}{dt} = 0\} \text{ is the singleton } \{E_{0P}\}, \text{ where } E_{0P} \text{ is the endemic equilibrium point of the system (24) and by LaSalle's invariance principle [11, 16, 18], it implies \\ \text{that } E_{0P} \text{ is globally asymptotically stable in } \Omega_2 \text{ if } A < B. \end{split}$$

3.4 Analysis of the HIV/AIDS and PCP Co-Infection Model

In this subsection, the disease-free equilibrium E_0 , the basic reproduction number \mathcal{R}_0 , and the stability of model equilibria (1) are determined.

3.4.1 Disease-Free Equilibrium of HIV/AIDS and PCP Co-Infection Model

At disease-free equilibria, that is in absence of both HIV and PCP; $C(t) = I_P(t) = I_H(t) = I_T(t) = I_{HP}(t) = I_{AP}(t) = T(t) = 0$. Equating the right hand side of system (1) to zero and solving, gives $S(t) = \Lambda/\mu$ and R(t) = 0. Therefore, the disease-free equilibrium is obtained as $E_0 = (\Lambda/\mu, 0, 0, 0, 0, 0, 0, 0, 0, 0)$.

3.4.2 The Basic Reproduction Number of HIV/AIDS and PCP Co-Infection Model

In this case, \mathcal{R}_0 defines the number of secondary HIV or Pneumonia co-infections due to a single HIV or PCP infective. Thus, using the procedure earlier described in sub-subsection 3.2.2 on HIV/AIDS and PCP co-infection model (1), we let \mathcal{F} be the matrix for the rate of appearance of new PCP and HIV infections and \mathcal{V} be the matrix for the rate of other transfer terms such that;

.

$$\mathcal{F} = \begin{bmatrix} \xi \alpha_P(t) S(t) \\ (1-\xi) \alpha_P(t) S(t) \\ \alpha_H(t) \left(S(t) + R_P(t) \right) \\ 0 \\ \alpha_H(t) \left(C(t) + I_P(t) \right) + \alpha_P(t) I_H(t) \\ \alpha_P(t) I_A(t) \end{bmatrix} \text{ and } \mathcal{V} = \begin{bmatrix} (\alpha_H(t) + \beta + \pi + \mu) C(t) \\ -\beta C + (\alpha_H + \epsilon + \mu + \nu_P) I_P(t) \\ (\alpha_P(t) + \tau_1 + \lambda_1 + \mu) I_H(t) \\ (\alpha_P(t) + \tau_1 + \lambda_1 + \mu) I_H(t) \\ (\lambda_2 + \tau_3 + \mu + \nu_P) I_{PH}(t) \\ -\lambda_2 I_{HP} + (\tau_4 + \mu + \nu) I_{AP}(t) \end{bmatrix}$$

The Jacobian matrix F of new infections at disease-free equilibrium is given by

The Jacobian matrix V for the rate of transfer from one component to another at disease-free equilibrium is given by

$$V = \begin{bmatrix} k_1 & 0 & 0 & 0 & 0 & 0 \\ -\beta & k_2 & 0 & 0 & 0 & 0 \\ 0 & 0 & q_1 & 0 & 0 & 0 \\ 0 & 0 & -\lambda_1 & q_2 & 0 & 0 \\ 0 & 0 & 0 & 0 & d_1 & 0 \\ 0 & 0 & 0 & 0 & -\lambda_2 & d_2 \end{bmatrix},$$

where $k_1 = (\beta + \pi + \mu), k_2 = (\epsilon + \mu + \nu_P), q_1 = (\tau_1 + \lambda_1 + \mu), q_2 = (\tau_2 + \mu + \nu_A), d_1 = (\lambda_2 + \tau_3 + \mu + \nu_P)$ and $d_2 = (\tau_4 + \mu + \nu)$. Thus, the basic reproduction number is given by

$$\mathcal{R}_{0} = \mathcal{K}(FV^{-1}) = \max\{\mathcal{R}_{0P}, \mathcal{R}_{0H}\} = \max\{\frac{\rho c}{k_{1}k_{2}}\left(\xi(\omega k_{2} + \beta) + (1 - \xi)k_{1}\right), \frac{\eta k}{q_{1}q_{2}}\left(q_{2} + a_{2}\lambda_{1}\right)\}, \mathcal{R}_{0} = \mathcal{K}(FV^{-1})$$

where \mathcal{K} is the spectral radius of FV^{-1} .

3.4.3 Local stability of HIV/AIDS and PCP Free Equilibrium

Theorem 7. The disease-free equilibrium point E_0 of system (1) is locally asymptotically stable whenever $R_0 < 1$, and otherwise unstable.

Proof. The Jacobian matrix for system (1) evaluated at disease-free equilibrium is given by

	$-\mu$	$- ho c\omega$	$-\rho c$	γ	$-\eta k$	$-\eta ka_2$	0	$-(\rho c\theta_1 + \eta k a_1)$	$-(\rho c \theta_2 + \eta k a_3)$	0
$J_{(E_0)} =$	0	$\xi ho c \omega - k_1$	$\xi ho c$	0	0	0	0	$\xi ho c heta_1$	$\xi ho c \theta_2$	0
	0	$(1-\xi)\rho c\omega - k_1$	$(1-\xi)\rho c$	0	0	0	0	$(1-\xi)\rho c \theta_1$	$(1-\xi)\rho c\theta_2$	0
	0	π	ϵ	$-k_3$	0	0	0	0	0	0
	0	0	0	0	$\eta k - q_1$	ηka_2	0	ηka_1	ηka_3	0
	0	0	0	0	λ_1	$-q_{2}$	0	0	0	0
	0	0	0	0	$ au_1$	$ au_2$	$-\mu$	0	0	0
	0	0	0	0	0	0	0	$-q_{3}$	0	0
	0	0	0	0	0	0	0	λ_2	$-q_{4}$	0
	0	0	0	0	0	0	0	$ au_3$	$ au_4$	$-\mu$
	-								(37)	-

where $k_1 = (\beta + \pi + \mu), k_2 = (\epsilon + \mu + \nu_P), k_3 = (\gamma + \mu), q_1 = (\tau_1 + \lambda_1 + \mu), q_2 = (\tau_2 + \mu + \nu_A), q_3 = (\lambda_2 + \tau_3 + \mu + \nu_P)$ and $q_4 = (\tau_4 + \mu + \nu).$

Thus, from the Jacobian matrix (37), we get the following characteristic polynomial

$$P(\lambda) = (\lambda + \mu)^3 (\lambda + k_3) (\lambda + q_3) (\lambda + q_4) (\lambda^2 + a_1 \lambda + a_0) (\lambda^2 + b_1 \lambda + b_0),$$
(38)

where $a_1 = k_1 + k_2 - \rho c ((1 - \xi) + \xi \omega) > 0$, if $k_1 + k_2 > \rho c ((1 - \xi) + \xi \omega)$, $a_0 = k_1 k_2 - \rho c ((1 - \xi) k_1 + \xi (k_2 \omega + \beta)) = k_1 k_2 (1 - \mathcal{R}_{0P}) > 0$, if $\mathcal{R}_{0P} < 1$, $b_1 = q_1 + q_2 - \eta k > 0$, if $q_1 + q_2 > \eta k$, and $b_0 = q_1 q_2 - \eta k (q_2 + a_2 \lambda_1) = q_1 q_2 (1 - \mathcal{R}_{0P}) > 0$, if $\mathcal{R}_{0H} < 1$. This implies that $\lambda_1 = -\mu < 0$ (three times), $\lambda_2 = -k_3 < 0$, $\lambda_3 = -q_3 = < 0$, $\lambda_4 = -q_4 < 0$ and by Routh-Hurwitz stability criteria, the eigenvalues of characteristic equations $\lambda^2 + a_1 \lambda + a_0 = 0$ and $\lambda^2 + b_1 \lambda + b_0 = 0$ are negative if $a_0 > 0$, $a_1 > 0$, $b_0 > 0$ and $b_1 > 0$ which is true when $\mathcal{R}_{0P} < 1$ and $\mathcal{R}_{0H} < 1$. Therefore, since all eigenvalues of characteristic polynomial (38) are negative for $\mathcal{R}_0 < 1$, the disease-free equilibrium point of system (1) is locally asymptotically stable.

3.4.4 Existence of Endemic Equilibrium Point of System (1)

The HIV/AIDS and PCP co-infection endemic equilibrium point $E_e = (S^*, C^*, I_P^*, R^*, I_H^*, I_A^*, I_T^*, I_{HP}^*, I_{AP}^*, T^*)$ materializes when PCP, HIV/AIDS and their co-infection persevere in the community. It has already been established from the analysis of sub-models (5) and (24) that the endemic steady states do not exist when $\mathcal{R}_{0H} < 1$ and $\mathcal{R}_{0P} < 1$ respectively. This in turn signifies that there is no endemic equilibrium point of the full co-infection model (1) if $\mathcal{R}_0 = \max{\{\mathcal{R}_{0H}, \mathcal{R}_{0P}\}} < 1$.

The analytical computation of the endemic equilibrium of the full model (2) in terms of model parameters is strenuous; however, it exists when $\mathcal{R}_{0H} > 1$ and $\mathcal{R}_{0P} > 1$, that is $\mathcal{R}_0 = \max{\{\mathcal{R}_{0H}, \mathcal{R}_{0P}\}} > 1$. The existence and stability of the endemic equilibrium point $E_e = (S^*, C^*, I_P^*, R^*, I_H^*, I_A^*, I_T^*, I_{HP}^*, I_{AP}^*, T^*)$ will be numerically scrutinized under numerical simulations.

3.5 Sensitivity analysis

In order to determine how to reduce the burden due to HIV/AIDS, PCP and their co-infection, we calculate the sensitivity indices of the basic reproduction number, \mathcal{R}_0 with respect to the parameters in the model using the approach in [6, 10]. Sensitivity analysis determines parameters that have a high impact on \mathcal{R}_0 and hence which parameters should be targeted for intervention strategies. The sensitivity index of \mathcal{R}_0 with respect to a parameter, x is given by $\Lambda_x^{\mathcal{R}_0} = \frac{\partial \mathcal{R}_0}{\partial x} * \frac{x}{\mathcal{R}_0}$.

The sensitivity indices of \mathcal{R}_{0H} and \mathcal{R}_{0P} with respect to parameters are given in Table 2.

Parameter symbol	Sensitivity Index (\mathcal{R}_{0H})	Parameter symbol	Sensitivity Index (\mathcal{R}_{0P})
η	+1.0000	ho	+1.0000
k	+1.0000	c	+1.0000
a_2	+0.1519	ξ	+0.1953
λ_1	-0.0747	ω	+0.4360
$ au_1$	-0.5666	$ u_P$	-0.1512
$ au_2$	-0.0368	eta	-0.0224
λ_1	-0.0747	ϵ	-0.3024
$ u_A $	-0.0944	π	-0.0563

Table 2: Numerical values of sensitivity indices of \mathcal{R}_{0H} and \mathcal{R}_{0P}

It is noted that the value of \mathcal{R}_0 increases when parameter values η , k, a_2 , ρ , ξ , c and ω increase while the other parameters values are kept constant since they have positive indices, and this implies that the endemicity of the disease is increased.

On the other hand, when parameters τ_1 , τ_2 , λ_1 , ν_A , ϵ , β , ν_P and π are increased while the other parameters values are kept constant, the value of \mathcal{R}_0 decreases implying that the endemicity of the disease is decreased.

4 Numerical Simulations

In this section, we numerically simulate the stability of the endemic equilibrium point for the full co-infection model (1), the contribution of PCP carriers to the HIV/AIDS-PCP co-infection burden and the effect of treatment on the control of the co-infection burden. With data set in Table 3 and initial conditions; $S_0 = 10000, C_0 = 200, I_{P0} = 250, R_0 = 150, I_{H0} = 400, I_{A0} = 250, I_{T0} = 300, I_{HP0} = 350, I_{AP0} = 150, T_0 = 150, the model was simulated using ODE solvers coded in MATLAB numerical solver.$

Parameter	$Value(year^{-1})$	Source	Parameter	$Value(year^{-1})$	Source
Λ	2000	Assumed	γ	0.0621	Assumed
μ	0.073	[20]	η	0.075	[1]
k	1-5	Estimated	ho	0.89-0.99	[33]
c	1-50	Assumed	ϵ	0.2	Assumed
ω	0.41026	Assumed	π	0.0115	Assumed
β	0.01096	Assumed	ν_P	0.1	Assumed
$ u_A$	0.333	[31]	ν	0.42	[31]
$ au_1$	0.2	Estimated	$ au_2$	0.13	[32]
$ au_3$	0.314	Assumed	$ au_4$	0.230	[32]
ξ	0.338	Assumed	λ_1,λ_2	0.08, 0.3105	[31]
a_1, a_2, a_3	1, 1.2, 1.4	Assumed	$ heta_1, heta_2$	$1,\!1.02$	Assumed

Table 3: Parameter values used in numerical simulations

4.1 Stability of the Endemic Equilibrium Point

Figure 2 shows the local stability of the endemic equilibrium of the HIV/AIDS and PCP co-infection model at $\mathcal{R}_{0H} = 1.0021 > 1$ and $\mathcal{R}_{0P} = 11.6601 > 1$. Since the system moves to equilibrium after 40 years from the initial populations, we conclude that the endemic equilibrium point is locally asymptotically stable. Figure 3 indicates that the PCP and HIV/AIDS co-infection endemic equilibrium is globally stable since the system comes to equilibrium from any possible initial conditions.



Figure 2: The local stability of the endemic equilibrium point at $\mathcal{R}_{0H} = 1.0021$ and $\mathcal{R}_{0P} = 11.6601$.



Figure 3: The Global stability of the endemic equilibrium point.



Figure 4: Effect of PCP Carriers infectivity on Co-dynamics of HIV/AIDS and PCP.

4.2 Visualization of the Role Played by PCP Carriers in Co-infection Dynamics of HIV/AIDS and PCP.

Numerical simulations in Figure 4 show the effect of varying the infectious coefficient of PCP carriers on the PCP carrier, PCP infective and HIV/AIDS-PCP co-infected populations. As the value of ω is altered from 0.2-0.8, Figure 4 affirms that the PCP carrier, PCP infective and the co-infected populations also increase. This is a clear indicator that the contribution of PCP carriers in the transmission dynamics of PCP and its association with HIV/AIDS should not be given a blind eye.

Simulations in Figures 5 to 7 show the effect of interrupting PCP through treatment effort at different phases of infection. Increasing the treatment rate of PCP carriers π from 0.0115 – 0.40, Figure 5 shows that the number of dually infected individuals reduce. Figure (6) shows that increasing the treatment rate of PCP infectives ϵ from 0.2 – 0.5, results in a decline in number HIV/AIDS-PCP co-infected individuals. The impact of increasing dual treatment rates τ_3 from 0.314 – 0.530 and τ_4 from 0.23 – 0.46 are observed to

The impact of increasing dual treatment rates τ_3 from 0.314 – 0.530 and τ_4 from 0.23 – 0.46 are observed to reduce the number of HIV-PCP and AIDS-PCP co-infectives in Figure 7.

5 Discussion and Conclusion

In this paper, an HIV/AIDS and PCP co-infection model is derived and analyzed. The basic properties of the model are shown and it is established that the model is biologically meaningful and well posed.

The disease-free steady states E_{0H} for HIV/AIDS sub-model, E_{0P} for PCP sub-model, E_0 for the dual infection and their corresponding reproduction numbers \mathcal{R}_{0H} , \mathcal{R}_{0P} , \mathcal{R}_0 are derived. It is established that



4.3 Visualization of the Effect of Treatment at Various Stages of Infections

Figure 5: Role of treating PCP carriers on HIV/AIDS-Pneumonia Co-dynamics.



Figure 6: Effect of treating PCP infectives on HIV/AIDS-Pneumonia Co-dynamics.



Figure 7: Effect of Dual treatment on HIV-PCP Co-dynamics.

the disease-free steady states are locally asymptotically stable when their respective basic reproduction numbers are less than a unity. The equilibria E_{0H} and E_{0P} are globally stable whenever $\mathcal{R}_{0H} \leq 1$ and $\mathcal{R}_{0P} \leq 1$ respectively. This means that HIV/AIDS infection, PCP infection and the HIV/AIDS-PCP coinfection will not prevail and will eventually be wiped out in the community.

Further analysis shows that the disease persistent equilibrium points E_{eH} for HIV/AIDS sub-model and E_{eP} for PCP sub-model, are unique if their corresponding reproduction numbers $\mathcal{R}_{0H} > 1$ and $\mathcal{R}_{0P} > 1$. By use of suitable Lyapunov functions, the equilibria E_{eH} and E_{eP} are globally asymptotically stable whenever $\mathcal{R}_{0H} > 1$ and $\mathcal{R}_{0P} > 1$ respectively. The local and global stability of the endemic equilibrium point E_e of the co-infection model is numerically determined and is shown to be stable if $\mathcal{R}_0 = \max{\mathcal{R}_{0H}, \mathcal{R}_{0P}} > 1$ in figures 2 and 3. This suggests that the HIV/AIDS infection, PCP infection and HIV/AIDS-PCP coinfection will surge when more than one HIV/AIDS or PCP or co-infected individuals are introduced in the community.

The sensitivity analysis of the basic reproduction number was carried out and results indicated that treatment is important in the reduction of PCP across all affected sub-groups. The co-efficient of transmission of PCP carriers gave a positive sensitivity index which implied that PCP carriers are silent spreaders of the infection and need to be interrupted in order to scale down the PCP incidence rate.

Numerical simulations show that increased infectivity of PCP carriers increases the number of PCP carriers, PCP infectives, HIV-PCP co-infectives and AIDS-PCP co-infectives as shown in figure 4. This calls for an alarm to the policy makers to introduce case finding strategy for PCP carriers since their contribution to PCP infection and its association with HIV/AIDS is enormous. This can also be achieved by testing all HIV infected individuals for a possible PCP infection and all positive cases subjected to PCP treatment. Furthermore, simulations dictate that increased rates of treatment of PCP carriers, PCP infectives, and dually infected individuals is of a great deal towards reducing the burden of PCP infection and its close association in HIV/AIDS patients.

We recommend that if HIV/AIDS and PCP co-infection burden is to be managed, all HIV infected individuals be subjected to obligatory PCP diagnosis and positive cases treated accordingly. It is clear that interrupting PCP at all contagious phases by treating PCP carriers, PCP infectives and HIV/AIDS-PCP co-infectives will scale down the burden of PCP on individuals living with HIV/AIDS.

The model is not without limitations. The model did not take into consideration of immigration of carriers, infected and co-infected individuals into the system, HIV infected individuals were not split into chronic and acute subgroups, individuals who default ART were also not included. Incorporating these processes will undoubtedly facilitate in the understanding of HIV/AIDS and PCP co-infection transmission and control dynamics.

Author Contributions

Michael Byamukama: Conceptualization, analysis and manuscript preparation.Damian Kajunguri: Supervision and interpretation of results.Martin Karuhanga: Supervision, analysis and proofreading.

Conflict of Interest

The authors declare that they have no conflicting interests.

References

- Bhunu, C. P., Garira, W., & Mukandavire, Z. (2009). Modeling HIV/AIDS and tuberculosis coinfection. Bulletin of mathematical biology, 71(7), 1745.
- [2] Bhunu, C. P., Mushayabasa, S., Kojouharov, H., & Tchuenche, J. M. (2011). Mathematical analysis of an HIV/AIDS model: impact of educational programs and abstinence in sub-Saharan Africa. *Journal of Mathematical Modelling and Algorithms*, 10, 31-55.
- [3] Bozorgomid, A., Hamzavi, Y., Khayat, S. H., Mahdavian, B., & Bashiri, H. (2019). Pneumocystis jirovecii pneumonia and human immunodeficiency virus co-infection in Western Iran. *Iranian Journal of Public Health*, 48(11), 2065.

- [4] Carreto-Binaghi, L. E., Morales-Villarreal, F. R., García-de la Torre, G., Vite-Garín, T., Ramirez, J. A., Aliouat, E. M., ... & Taylor, M. L. (2019). Histoplasma capsulatum and Pneumocystis jirovecii coinfection in hospitalized HIV and non-HIV patients from a tertiary care hospital in Mexico. International Journal of Infectious Diseases, 86, 65-72.
- [5] Castillo-Chavez, C., Feng, Z., Haung, W. (2002). On the computation of R_0 and its role on global stability. Mathematical approaches for emerging and reemerging infectious diseases: an introduction, 1, 229.
- [6] Chitnis, N., Hyman, J. M., & Cushing, J. M. (2008). Determining important parameters in the spread of malaria through the sensitivity analysis of a mathematical model. *Bulletin of mathematical biology*, 70, 1272-1296.
- [7] Cillóniz, C., Dominedò, C., Álvarez-Martínez, M. J., Moreno, A., García, F., Torres, A., & Miro, J. M. (2019). Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients. *Expert review of anti-infective therapy*, 17(10), 787-801.
- [8] DeJesus, E. X., & Kaufman, C. (1987). Routh-Hurwitz criterion in the examination of eigenvalues of a system of nonlinear ordinary differential equations. *Physical Review A*, 35(12), 5288.
- [9] Diekmann, O., Heesterbeek, J. A. P., & Metz, J. A. (1990). On the definition and the computation of the basic reproduction ratio R₀ in models for infectious diseases in heterogeneous populations. *Journal of* mathematical biology, 28, 365-382.
- [10] Ega, T. T., & Ngeleja, R. C. (2022). Mathematical Model Formulation and Analysis for COVID-19 Transmission with Virus Transfer Media and Quarantine on Arrival. *Computational and Mathematical Methods*, 2022.
- [11] Endashaw, E. E., & Mekonnen, T. T. (2022). Modeling the effect of vaccination and treatment on the transmission dynamics of hepatitis B virus and HIV/AIDS coinfection. *Journal of Applied Mathematics*, 2022, 1-27.
- [12] Fauci, A. S., & Lane, H. C. (2020). Four decades of HIV/AIDS much accomplished, much to do. New England Journal of Medicine, 383(1), 1-4.
- [13] Fishman, J. A. (2020, February). Pneumocystis jiroveci. In Seminars in Respiratory and Critical Care Medicine (Vol. 41, No. 01, pp. 141-157). Thieme Medical Publishers.
- [14] Ho, D. D. (1995). Time to hit HIV, early and hard. New England Journal of Medicine, 333(7), 450-451.

- [15] Huang, Y. S., Yang, J. J., Lee, N. Y., Chen, G. J., Ko, W. C., Sun, H. Y., & Hung, C. C. (2017). Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review. *Expert review of anti*infective therapy, 15(9), 873-892.
- [16] Kamara, T., Byamukama, M., & Karuhanga, M. (2022). Modelling the Role of Treatment, Public Health Education, and Chemical Control Strategies on Transmission Dynamics of Schistosomiasis. *Journal of Mathematics*, 2022.
- [17] Kato, H., Samukawa, S., Takahashi, H., & Nakajima, H. (2019). Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients—difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole. *Journal of Infection and Chemotherapy*, 25(11), 920-924.
- [18] LaSalle, J. P. (1976). Stability theory and invariance principles. In Dynamical systems (pp. 211-222). Academic Press.
- [19] Lowe, D. M., Rangaka, M. X., Gordon, F., James, C. D., & Miller, R. F. (2013). Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression. *PloS one*, 8(8), e69969.
- [20] Mbabazi, F. K., Mugisha, J. Y. T., & Kimathi, M. (2020). Global stability of pneumococcal pneumonia with awareness and saturated treatment. *Journal of Applied Mathematics*, 2020, 1-12.
- [21] Medrano, F. J., Montes-Cano, M., Conde, M., De La Horra, C., Respaldiza, N., Gasch, A., ... & Calderon, E. J. (2005). Pneumocystis jirovecii in general population. *Emerging infectious diseases*, 11(2), 245.
- [22] Nah, K., Nishiura, H., Tsuchiya, N., Sun, X., Asai, Y., & Imamura, A. (2017). Test-and-treat approach to HIV/AIDS: a primer for mathematical modeling. *Theoretical Biology and Medical Modelling*, 14(1), 1-11.
- [23] Nannyonga, B., Mugisha, J. Y. T., & Luboobi, L. S. (2011). The role of HIV positive immigrants and dual protection in a co-infection of malaria and HIV/AIDS. *Applied Mathematical Sciences*, 5(59), 2919-2942.
- [24] Nthiiri, J. K., Lavi, G. O., & Manyonge, A. (2015). Mathematical model of pneumonia and HIV/AIDS coinfection in the presence of protection.
- [25] Omondi, E. O., Mbogo, R. W., & Luboobi, L. S. (2018). Mathematical modelling of the impact of testing, treatment and control of HIV transmission in Kenya. *Cogent Mathematics & Statistics*, 5(1), 1475590.

- [26] Oshinubi, K., Peter, O. J., Addai, E., Mwizerwa, E., Babasola, O., Nwabufo, I. V., ... & Agbaje, J. O. (2023). Mathematical modelling of tuberculosis outbreak in an East African country incorporating vaccination and treatment. *Computation*, 11(7), 143.
- [27] Peter, O. J., Panigoro, H. S., Abidemi, A., Ojo, M. M., & Oguntolu, F. A. (2023). Mathematical model of COVID-19 pandemic with double dose vaccination. Acta biotheoretica, 71(2), 9.
- [28] Rodríguez, Y. D. A., Wissmann, G., Müller, A. L., Pederiva, M. A., Brum, M. C., Brackmann, R. L., ...& Calderón, E. J. (2011). Pneumocystis jirovecii pneumonia in developing countries. *Parasite: journal* de la Société Française de Parasitologie, 18(3), 219.
- [29] Salzer, H. J., Schäfer, G., Hoenigl, M., Günther, G., Hoffmann, C., Kalsdorf, B., ... & Lange, C. (2018). Clinical, diagnostic, and treatment disparities between HIV-infected and non-HIV-infected immunocompromised patients with Pneumocystis jirovecii pneumonia. *Respiration*, 96(1), 52-65.
- [30] Tasaka, S. (2020). Recent advances in the diagnosis and management of Pneumocystis pneumonia. *Tuberculosis and Respiratory Diseases*, 83(2), 132.
- [31] Teklu, S. W., & Mekonnen, T. T. (2021). HIV/AIDS-pneumonia coinfection model with treatment at each infection stage: mathematical analysis and numerical simulation. *Journal of Applied Mathematics*, 2021, 1-21.
- [32] Teklu, S. W., & Rao, K. P. (2022). HIV/AIDS-pneumonia codynamics model analysis with vaccination and treatment. *Computational and Mathematical Methods in Medicine*, 2022.
- [33] Tilahun, G. T., Makinde, O. D., & Malonza, D. (2017). Modelling and optimal control of pneumonia disease with cost-effective strategies. *Journal of Biological Dynamics*, 11(sup2), 400-426.
- [34] UNAIDS, Global HIV statistics 2022 fact sheet, updated July 2022.
- [35] Van den Driessche, P., & Watmough, J. (2002). Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. *Mathematical biosciences*, 180(1-2), 29-48.
- [36] Wills, N. K., Lawrence, D. S., Botsile, E., Tenforde, M. W., & Jarvis, J. N. (2021). The prevalence of laboratory-confirmed Pneumocystis jirovecii in HIV-infected adults in Africa: A systematic review and meta-analysis. *Medical mycology*, 59(8), 802-812.
- [37] Yoshimura, K. (2017). Current status of HIV/AIDS in the ART era. Journal of Infection and Chemotherapy, 23(1), 12-16.